20S Immunoproteasome (human) (untagged)

South Bay Bio

20S Immunoproteasome (human) (untagged)

10

Research Use Only

>95%

Protein. Human 20S Immunoproteasome. Source: Human PBMCs. Formulation: Liquid. In 50mM HEPES pH 7.5, 100mM sodium chloride, 1mM TCEP. Purity: >95% (SDS-PAGE). The 20S immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of alpha-subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasomes these subunits (beta1, beta2, beta5) are replaced by three inducible subunits: PSMB9, PSMB10 and PSMB8, (beta1i, beta2i, beta5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T cells. 20S immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer. - The 20S immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of alpha-subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasomes these subunits (beta1, beta2, beta5) are replaced by three inducible subunits: PSMB9, PSMB10 and PSMB8, (beta1i, beta2i, beta5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T cells. 20S immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer.

-80°C

12352202